Recent research (15) have demonstrated that an intermittent fasting regimen of 5:2 effectively prevents the onset of non-alcoholic steatohepatitis (NASH) and improves both established NASH and fibrosis without altering overall caloric consumption, furthermore, this research has also elucidated the cooperative roles of peroxisome proliferator-activated receptor alpha (PPARα) and glucocorticoid signaling-induced phosphoenolpyruvate carboxykinase 1 (PCK1) as crucial hepatic mediators in the fasting response. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.